| 查看: 668 | 回复: 5 | |||
| 当前主题已经存档。 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
wuhaofei2006
|
[交流]
帮忙翻译一下呢！
|
||
|
Lung Cancer Vaccine Enters Large-scale Clinical Trial A new treatment for the most common form of lung cancer, developed from initial research by Cancer Research UK scientists, has entered a pivotal phase III clinical trial. The drug, called Stimuvax, is a type of therapeutic vaccine that targets a specific protein found in many tumours, including non-small cell lung cancer. It was developed by Canadian biotech company Biomira following Cancer Research UK-funded studies led by Professor Joyce Taylor-Papadimitriou of Guy's Hospital, London. Biomira have already run phase II trials with very encouraging results. The international phase III trial, named START (Stimulating Targeted Antigenic Responses To NSCLC), is expected to enrol its first patient this month. Run by pharmaceutical company Merck KGaA, it will eventually include more than 1,300 lung cancer patients in 30 countries, including the UK. Therapeutic vaccines are a relatively new development in cancer treatment. Unlike preventative vaccines, they are treatments that induce the body's own immune system to identify and kill existing cancer cells. Stimuvax is designed to stimulate the immune system to recognise and react to a molecule called MUC1, which is much more abundant on tumour cells than healthy cells. The immune system then kills the cancer cells with MUC1, hopefully without overly harming healthy cells. Cancer Research Technology Limited (CRT), Cancer Research UK's development and commercialisation company, licensed a number of discoveries to Biomira, which led to the development of Stimuvax for advanced non small cell lung cancer. Merck KGaA also plans to investigate the use of Stimuvax for other types of cancer. Dr Keith Blundy, chief operating officer of CRT, said: "We are extremely pleased that Stimuvax has entered the final stage of clinical trials. The drug is one of CRT's portfolio of more than 20 partnered agents in clinical development. Targeted vaccines are an exciting approach that could potentially offer new treatment options for major types of cancer." Harpal Kumar, chief executive of CRT and chief operating officer of Cancer Research UK, said: "We're delighted that another drug based on Cancer Research UK-funded basic research has reached the final stage of clinical development. The 'translation' of basic research into patient benefit is the major focus of our work and we hope that new ventures, such as the expansion of our drug discovery activities across the country, will lead to many more such drugs entering trials in the future." Lung cancer -- Lung cancer is the second most common cancer in the UK after breast cancer, and the most common cancer worldwide. -- There were more than 37,000 cases of lung cancer diagnosed in the UK in 2003. -- Non small cell lung cancer accounts for 80 per cent of total lung cancer cases. -- Current standard treatments for lung cancer patients are surgery, platinum-based combination chemotherapy and radiotherapy. START trial In the trials, Stimuvax will be compared to a placebo. More information on the START trial can be found here. Research centres in Edinburgh, Leeds and Exeter will be participating in the trial. For more information about clinical trials in the UK, visit Cancer Research UK's patient information website, CancerHelp UK. Cancer Research Technology Cancer Research Technology Limited (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found here. About Cancer Research UK Together with its partners and supporters, Cancer Research UK's vision is to beat cancer. -- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer. -- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients. -- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make. -- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer. |
回复此楼» 猜你喜欢
如何理解hopf map
已经有0人回复
-
提取肿瘤组织消化后得到的肿瘤细胞死亡率过高
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有104人回复
-
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
求购时间长一些的硝酸钍
已经有0人回复
-
跪求一支AAV293细胞
已经有1人回复
6楼2007-06-11 23:37:49
回复: 翻译稿
★ ★ ★
qcbnj(金币+3):谢谢参与
qcbnj(金币+3):谢谢参与
|
Lung Cancer Vaccine Enters Large-scale Clinical Trial 肺癌疫苗研究进入大规模临床研究阶段 A new treatment for the most common form of lung cancer, developed from initial research by Cancer Research UK scientists, has entered a pivotal phase III clinical trial. 最常见的癌症治疗的新药物已进入了III临床研究的关键阶段，该药物是由英国癌症科学家最开始研究的。 The drug, called Stimuvax, is a type of therapeutic vaccine that targets a specific protein found in many tumours, including non-small cell lung cancer. It was developed by Canadian biotech company Biomira following Cancer Research UK-funded studies led by Professor Joyce Taylor-Papadimitriou of Guy's Hospital, London. Biomira have already run phase II trials with very encouraging results. Stimuvax是一种治疗性疫苗，作用靶位是包括非小细胞癌症许多肿瘤中发现的一种特殊蛋白。它是由加拿大生物科技公司BIOMIRA应英国伦敦GUY医院教授Joyce Taylor-Papadimitriou领头的英国癌症研究资助的研究而研发的。Stimuvax II临床已经完成，并取得了可喜的结果。 The international phase III trial, named START (Stimulating Targeted Antigenic Responses To NSCLC), is expected to enrol its first patient this month. Run by pharmaceutical company Merck KGaA, it will eventually include more than 1,300 lung cancer patients in 30 countries, including the UK. 被称做START（对非小细胞肺癌的刺激靶向抗原响应）III临床研究应该将该月治疗的第一例病人做登记。Merck KGaA 制药公司进行的研究最终将涉及包括英国在内的30个国家的1300多癌症病人。 Therapeutic vaccines are a relatively new development in cancer treatment. Unlike preventative vaccines, they are treatments that induce the body's own immune system to identify and kill existing cancer cells. Stimuvax is designed to stimulate the immune system to recognise and react to a molecule called MUC1, which is much more abundant on tumour cells than healthy cells. The immune system then kills the cancer cells with MUC1, hopefully without overly harming healthy cells. 治疗性疫苗是一种相对新的癌症治疗方法。不象预防性疫苗，治疗性疫苗是使自身免疫系统识别并杀死癌症细胞。Stimuvax设计思路是刺激免疫系统识别被称为MUC1的分子并对其做出反应，然后免疫系统将杀死含有MUC1分子的癌症细胞，希望不会过度杀害正常细胞。MUC1在肿瘤细胞要比正常细胞上多。 Cancer Research Technology Limited (CRT), Cancer Research UK's development and commercialisation company, licensed a number of discoveries to Biomira, which led to the development of Stimuvax for advanced non small cell lung cancer. Merck KGaA also plans to investigate the use of Stimuvax for other types of cancer. 癌症研究技术有限、英国癌症研究发展和商业公司注册了到BIOBIRA许多发现，这使得Stimuvax发展成为非小细胞肺癌的晚期治疗药。Merck KgaA 公司也计划调研Stimuvax治疗其它类型的癌症使用情况。 Dr Keith Blundy, chief operating officer of CRT, said: "We are extremely pleased that Stimuvax has entered the final stage of clinical trials. The drug is one of CRT's portfolio of more than 20 partnered agents in clinical development. Targeted vaccines are an exciting approach that could potentially offer new treatment options for major types of cancer." CRT公司经营主管Keith Blundy 博士称：“我们很高兴Stimuvax进入临床研究的最后阶段。 该药是CRT公司临床研究的20多种中重要的药物之一。靶位疫苗是一种鼓舞人心的治疗方法，该治疗方法有为主要类型的癌症提供新治疗方法的潜力。 Harpal Kumar, chief executive of CRT and chief operating officer of Cancer Research UK, said: "We're delighted that another drug based on Cancer Research UK-funded basic research has reached the final stage of clinical development. The 'translation' of basic research into patient benefit is the major focus of our work and we hope that new ventures, such as the expansion of our drug discovery activities across the country, will lead to many more such drugs entering trials in the future." CRT的CEO兼英国癌症研究的经营主管Harpal Kumar称：“很高兴基于英国癌症研究资助的基础研究的另一药物近入了临床研究的最后阶段，我们现在关注的是将基础研究转化为病人受益，我们希望如全国范围内的药物研究这样的新尝试在将来将会使更多药物进入研究阶段。” Lung cancer 肺癌 -- Lung cancer is the second most common cancer in the UK after breast cancer, and the most common cancer worldwide. --在英国肺癌是继乳腺癌之后的第二常见癌症，是世界上最常见的癌症 -- There were more than 37,000 cases of lung cancer diagnosed in the UK in 2003. 2003年英国被确诊为肺癌的超过37000例。 -- Non small cell lung cancer accounts for 80 per cent of total lung cancer cases. --非小细胞肺癌在肺癌中占80%。 --Current standard treatments for lung cancer patients are surgery, platinum-based combination chemotherapy and radiotherapy. --肺癌当前的标准治疗方法有手术、基于铂的化学和放射联合疗法。 START trial START 研究 In the trials, Stimuvax will be compared to a placebo. More information on the START trial can be found here. 在临床研究中，Stimuvax将与安慰剂做对比。关于START 研究的更多信息将可以在这里看到。 Research centres in Edinburgh, Leeds and Exeter will be participating in the trial. 研究中心设在爱丁堡，利兹和埃克塞特也将参与。 For more information about clinical trials in the UK, visit Cancer Research UK's patient information website, CancerHelp UK. 英国临床研究的更多信息请参看英国癌症病人癌症研究信息网-英国癌症救助。 Cancer Research Technology 癌症研究技术 Cancer Research Technology Limited (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found here. 癌症研究技术有限公司（CRT）是一家专业的商业开发公司，其宗旨是在癌症研究中作出有益于病人的新发现。CRT与领先的世界癌症科学家及其机构密切合作，以保护研究中出现的知识产权问题及与商业合作者建立联系。CRT推动癌症新的治疗方法、疫苗、诊断学及可行性技术的发现、研发及市场化。CRT是由世界最大的独立的癌症研究基金-英国癌症研究-完全所有。 About Cancer Research UK 英国癌症研究 Together with its partners and supporters, Cancer Research UK's vision is to beat cancer. 英国癌症研究和其合作者及支持者的目标是战胜癌症。 -- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer. --英国癌症研究开展世界级的研究，以提高对各种癌症的认识，并寻找预防、诊断及治疗方法。 -- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients. --英国癌症研究确定研究结果用于提高所有癌症病人的生命。 -- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make. --英国癌症研究帮助人们认识癌症、病变进程及帮助人们做出选择。 -- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer. --英国癌症研究和其它合作者在全球抗癌中取得了重大影响。 可以的话别忘给鼓励呀 !  |
2楼2007-06-09 23:26:41
wuhaofei2006 
银虫 (正式写手)
- 应助: 0 (幼儿园)
- 金币: 97.6
- 散金: 315
- 红花: 24
- 帖子: 357
- 在线: 79.3小时
- 虫号: 180489
- 注册: 2006-02-09
- 性别: GG
- 专业: 疫苗学
3楼2007-06-11 08:03:25
4楼2007-06-11 08:41:55